Why the study?
Although hydromorphone attenuates myocardial ischaemia/reperfusion injury in rat models, its underlying mechanisms remained unclear.
Does hydromorphone improve cardiac function and reduce myocardial ischemia-reperfusion injury in rat and cell models?
Does hydromorphone improve cardiac function and reduce myocardial ischemia-reperfusion injury in rat and cell models?
Hydromorphone exerts protective effects against myocardial ischemia-reperfusion injury by suppressing NLRP3 inflammasomes in preclinical models.
No practice change warranted; leaves open human translation of hydromorphone’s NLRP3-mediated cardioprotection in MIRI.
Background: Myocardial ischaemia/reperfusion, MI/R injury causes significant cardiac damage, leading to disability and mortality. Although hydromorphone attenuates MI/R injury in rat models, its underlying mechanisms remain unclear. Objective: This study aimed to investigate the protective effects of hydromorphone against MI/R injury and elucidate its mechanisms. Methods: A rat MIRI model was established by occluding the left coronary artery for 30 minutes followed by reperfusion for 120 minutes. Infarct size and cardiac function were assessed using hematoxylin-eosin, HE and Masson's staining. An in vitro model was established using H9C2 cells subjected to hypoxia/reoxygenation, and levels of cellular pyroptosis and pyroptosis-related proteins were quantified. Results: Hydromorphone significantly improved cardiac function in MIRI rats. Pre- and post-treatment with hydromorphone significantly improved cardiomyocyte morphology in MIRI rats. In addition, compared with the model group (IR), the hydromorphone-treated groups (HH+IR, IR+HH) significantly reduced the rna expression of NLRP3, ASC, caspase-1, IL-1β, and IL-18, as well as the protein levels of IL-1β, IL-18. In addition, transmission electron microscopy showed that hydromorphone attenuated CoCl2-induced cardiomyocyte injury. Conclusion: Pre- or post-treatment with hydromorphone exerts protective effects against MIRI by suppressing NLRP3 inflammasomes, potentially providing a theoretical basis for its use as a therapeutic agent in MIRI patients.
No takes yet. Share an insight, caveat, or question.
Zeng et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: